Bellicum Pharmaceuticals, Inc.
🏢 View company profile →10Patents
10Active
10Granted
49Portfolio score
Filing activity: Sep 19, 2012 → Feb 11, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9434935B2 | Modified caspase polypeptides and uses thereof | Chemistry; Metallurgy | 17 | Active |
| US8486693B2 | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods | Chemistry; Metallurgy | 17 | Active |
| US9913882B2 | Methods for inducing partial apoptosis using caspase polypeptides | Chemistry; Metallurgy | 11 | Active |
| US9944690B2 | Methods for controlling T cell proliferation | Chemistry; Metallurgy | 9 | Active |
| US10525110B2 | Methods for inducing partial apoptosis using caspase polypeptides | Chemistry; Metallurgy | 3 | Active |
| US10888608B2 | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides | Emerging Cross-Sectional Technologies | 3 | Active |
| US10934346B2 | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 | Emerging Cross-Sectional Technologies | 1 | Active |
| US9932572B2 | Modified Caspase polypeptides and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US10918705B2 | Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides | Emerging Cross-Sectional Technologies | 0 | Active |
| US11839647B2 | Methods for inducing partial apoptosis using caspase polypeptides | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.